Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
hey, that new 15001 candidate looks incredibly promising!
It's just in mice thus far, so the odds are a bit long, but if it works in people, we'd be on top of the immunological world!
Blue fin: Are we waiting for a big pharma 15001 partner to be announced?
http://www.businesswire.com/news/home/20161115006621/en/Piper-Jaffray-Host-28th-Annual-Healthcare-Conference
Piper Jaffray to Host 28th Annual Healthcare Conference
November 15, 2016 02:25 PM Eastern Standard Time
NEW YORK--(BUSINESS WIRE)--Piper Jaffray Companies (NYSE: PJC), a leading investment bank and asset management firm, will host its 28th annual Healthcare Conference in New York on November 29-30, 2016.
Some more expectations for R&D day.
http://www.streetinsider.com/Analyst+Comments/Compugens+(CGEN)+COM701+Could+Make+R%26D+Day+A+Catalyst+-+FBR/12289666.html
Compugen's (CGEN) COM701 Could Make R&D Day A Catalyst - FBR
November 29, 2016 6:50 AM EST
FBR Capital analyst, Vernon Bernadino, reiterated his Outperform rating on shares of Compugen (NASDAQ: CGEN) as COM701 emerges shifts from ....
My guess is that the PPS will keep yo-yoing around until we see some of our findings turned into successful drugs...Or at least start selling some of them for a fair price.
The longer we don't, the greater BP's in silica capabilities will grow.
Stock price warmed up nicely on Friday and given 3x normal volume I wonder if we hit new 52 week high shortly
The hot, multibillion dollar drugs in immune oncology now are PD-1 inhibitors.
CGEN has a fat double handful more checkpoint inhibitors ready for testing with more coming.
I don't understand why BP isn't swarming all over them waving fat multi million dollar deals at us?
$CGEN recent news/filings
bullish 7.54
resistance breakout
uptrending higher highs higher lows
## source: finance.yahoo.com
Wed, 25 Nov 2015 23:28:49 GMT ~ Seneca Foods Corp (SENEA): Are Hedge Funds Right About This Stock?
read full: http://www.insidermonkey.com/blog/seneca-foods-corp-senea-are-hedge-funds-right-about-this-stock-389296/
*********************************************************
Tue, 24 Nov 2015 13:13:38 GMT ~ Compugen to Present at the Oppenheimer Healthcare Conference in New York
[at noodls] - 263e58e9-e35a-4356-879d-b0c60673032c.pdf FOR IMMEDIATE RELEASE Tel Aviv, Israel - November 24, 2015 - Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari ...
read full: http://www.noodls.com/view/7B34337F6D7EA3237CEF57A94685982ED7E6C8C6
*********************************************************
Tue, 24 Nov 2015 12:00:00 GMT ~ Compugen to Present at the Oppenheimer Healthcare Conference in New York
[Business Wire] - Compugen Ltd. , a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial Officer of Compugen, will present a corporate overview and update at the Oppenheimer 26th Annual Healthcare Conference in New York, on Tuesday, December 8, 2015.
read full: http://finance.yahoo.com/news/compugen-present-oppenheimer-healthcare-conference-120000947.html
*********************************************************
Thu, 12 Nov 2015 13:16:03 GMT ~ Compugen to Present at Jefferies 2015 Global Healthcare Conference in London
[at noodls] - 90f60e8b-731a-4e9b-86f8-2872812c6014.pdf FOR IMMEDIATE RELEASE Tel Aviv, Israel - November 12, 2015 - Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Dr. ...
read full: http://www.noodls.com/view/6A77E2809F38C15DC5F1A3886329C7713FAA308D
*********************************************************
Thu, 12 Nov 2015 12:00:00 GMT ~ Compugen to Present at Jefferies 2015 Global Healthcare Conference in London
read full: http://uk.finance.yahoo.com/news/compugen-present-jefferies-2015-global-120000514.html
*********************************************************
$CGEN charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CGEN company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CGEN/company-info
Ticker: $CGEN
OTC Market Place: Not Available
CIK code: 0001119774
Company name: Compugen Ltd.
Company website: http://www.cgen.com
Incorporated In:
$CGEN share structure
## source: otcmarkets.com
Market Value: $378,918,870 a/o Nov 27, 2015
Shares Outstanding: 50,254,492 a/o Dec 31, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$CGEN extra dd links
Company name: Compugen Ltd.
Company website: http://www.cgen.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CGEN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CGEN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CGEN+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CGEN/news - http://finance.yahoo.com/q/h?s=CGEN+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CGEN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CGEN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CGEN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CGEN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Compugen+Ltd.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Compugen+Ltd.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Compugen+Ltd.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.cgen.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.cgen.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.cgen.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CGEN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001119774&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CGEN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CGEN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CGEN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CGEN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CGEN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CGEN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CGEN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CGEN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CGEN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CGEN+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CGEN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CGEN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CGEN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CGEN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CGEN/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CGEN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CGEN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CGEN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CGEN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CGEN
$CGEN DD Notes ~ http://www.ddnotesmaker.com/CGEN
I'm in at $7. Long term hold. I think this company has great potential.
Oh great the market is way down today too! I have a feeling this thing could open higher and drop. My opinion
Explains the huge pps drop!
Compugen Ltd. Prices Public Offering of Ordinary Shares
Friday 28 February 2014
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) today announced that it has priced an underwritten public offering of 6,000,000 ordinary shares at a price to the public of $10.50 per share. Gross proceeds to Compugen are expected to be $63 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Compugen. The offering is expected to close on or about March 5, 2014, subject to satisfaction of customary closing conditions. Compugen has granted the underwriters a thirty (30) day option to purchase up to 900,000 additional ordinary shares.
9:27AM Compugen announced that it is significantly increasing its Pipeline Program activities in the field of immuno-oncology (CGEN) 9.53 :
Co announced that it is significantly increasing its Pipeline Program activities in the field of immuno-oncology. The primary purpose of the increase is to allow research and preclinical activities for a larger number of checkpoint target and product candidates for cancer immunotherapy to move forward in parallel. Additional objectives include the establishment of a biomarker discovery program for certain of the Company's checkpoint product candidates and the acceleration of experimental validation efforts for the recently disclosed antibody drug conjugate target candidates for oncology.
The significant increase in immuno-oncology activities during 2014 will impact both the target research and validation activities performed in Israel and the therapeutic antibody development efforts against Compugen-discovered drug targets undertaken by the Company's U.S. R&D subsidiary. This includes the scheduled relocation of the U.S. subsidiary to larger facilities in the South San Francisco area in mid-year.
"These expanded activities are anticipated to result in more than a sixty percent increase in our annual R&D cash expenditures, from approximately $10 mln in 2013 to more than $16 mln budgeted for 2014. Having begun 2014 with more than $50 mln in available resources, we are confident that this increased R&D budget, providing for a substantially expanded program in oncology while maintaining approximately the same level of expenditures for the immunology arm of our Pipeline Program, is fully consistent with our financial status and outlook."
7:01AM Compugen discloses discovery of five potential cancer targets for antibody drug conjugate therapy (CGEN) 9.18 : Co announces the predictive discovery and selection of five candidate targets for antibody-drug conjugate cancer therapy. These five potential ADC targets, representing the initial results from the Company's second focused in silico discovery program, are now entering initial experimental validation to be followed by antibody discovery and development activities. Initial results are expected during the second half of 2014.
ADC target discovery is Compugen's second focused in silico discovery program, following the success of its first focused discovery program for the discovery of immune checkpoint targets for treatment of cancer and immune diseases.
Compugen Discloses Discovery of Five Potential Cancer Targets for Antibody Drug Conjugate Therapy
Wednesday 11 December 2013
ADC target discovery is Company’s second focused discovery program utilizing its in silico predictive discovery infrastructure
Compugen Ltd. (NASDAQ: CGEN) announced today the predictive discovery and selection of five candidate targets for antibody-drug conjugate (ADC) cancer therapy. These five potential ADC targets, representing the initial results from the Company’s second focused in silico discovery program, are now entering initial experimental validation to be followed by antibody discovery and development activities. Initial results are expected during the second half of 2014.
ADC therapy utilizes antibodies to selectively target proteins on the surface of cancer cells for the delivery of highly toxic chemicals. This selective delivery is designed to limit the damage to healthy tissues, thereby reducing the side effects as compared to chemotherapy. To date, two approved ADC drugs have demonstrated impressive clinical proof of concept for this exciting new class of oncology drugs, and there are multiple additional ADC drugs in clinical development. Therefore, the discovery of target proteins meeting the requirements for utilizing ADC technology in the treatment of cancer is an area of high industry interest.
ADC target discovery is Compugen's second focused in silico discovery program, following the success of its first focused discovery program for the discovery of immune checkpoint targets for treatment of cancer and immune diseases. Compugen’s ADC target discovery program, which was initiated earlier this year, utilizes the same underlying predictive discovery infrastructure as the Company’s earlier immune checkpoint program, with the addition of certain algorithms and other computational capabilities specifically developed for this effort. In both programs, the objective is to first identify an appropriate set of proteins with the support of the Company’s proprietary predictive human proteome, and then select from this set those proteins predicted to have the highest probability of meeting each program’s specific requirements.
More specifically for the ADC program, Compugen’s discovery infrastructure was expanded by incorporating additional algorithms that enable prediction of membrane proteins having the potential to internalize, that are both expressed on cancer cells and have low expression on healthy cells, in order to allow the ADC drug to selectively attack the tumor and spare healthy tissues. It was additionally enhanced to identify targets associated with advanced cancer stages and poor clinical outcome, in order to provide potential superior first-in-class treatment to patient populations with limited therapeutic options.
Dr. Anat Cohen-Dayag, Compugen’s President and CEO stated, “As we continue to invest most of our R&D and commercialization efforts on activities supporting our current Pipeline Program product candidates, which are largely based on our immune checkpoint discoveries, we are pleased to disclose these promising initial discoveries from our second focused discovery program.”
Dr. Cohen-Dayag continued, “Immune checkpoint regulators are generally considered to be the next frontier in the treatment of cancer; however, ADCs are recognized as an additional very promising class of highly potent and selective oncology drugs providing a different approach to cancer treatment. Therefore, in view of our successful track record of experimental validation for molecules selected by our unique predictive discovery infrastructure, we very much look forward to the potential for these ADC target candidates to further expand the scope and diversity of the cancer therapy arm of our pipeline.”
Dr. Cohen-Dayag added, “These discoveries demonstrate significant advantages that our predictive discovery methodology offers compared with traditional discovery. First, since the required discovery platform for this program was built through the enhancement of our existing infrastructure, the total time to date has been less than a year from initiation of the program. Furthermore, this enhanced capability will now be available for future discovery programs. Second, since this second program utilizes a different basis for selection and prioritization of results than the first program, it further demonstrates the applicability of our core predictive infrastructure to multiple areas of high industry interest. Third, as demonstrated by both programs, each focused discovery program has the potential to yield multiple possible novel product candidates.”
About ADC Cancer Therapy
ADC cancer therapy destroys cancer cells by delivering high-potency cytotoxic agents (the “payload”) directly to the cancer cells. The principle underlying ADC therapy is linking the toxic agent payload to an antibody or antibody fragment that specifically targets a protein present on the membrane of the cancer cell. After administration to the patient, the antibody with the payload specifically binds this membrane protein on the cancer cell and is then internalized into the cell where the payload is released and destroys it. Thus, unlike chemotherapies, ADC therapy is designed to specifically destroy only cells displaying this protein by targeting the appropriate protein on the cancer cell. ADCs against a number of targets, both in solid and hematologic tumors, are in clinical development, with two ADC products gaining FDA approval in the past two years.
7:07AM Compugen presents experimental results supporting induction of immune tolerance by CGEN-15001 Drug Candidate; presentation will also disclose recent positive results from a humanized animal model of psoriasis (CGEN) 9.96 : Co disclosed results from an animal model study in which CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, demonstrated potential to induce immune tolerance, a much desired goal for treatment of many immunological disorders. The presentation will also disclose recent positive results from a humanized animal model of psoriasis, further expanding the scope of autoimmune conditions potentially treatable by CGEN-15001. In her presentation, Dr. Rotman will disclose results from a recently completed bone marrow transplantation study in which CGEN-15001 was highly effective in preventing graft rejection, suggesting that this drug candidate acts through an induction of immune tolerance. Establishment of immune tolerance is a key goal in the treatment of autoimmune diseases. In comparison to current therapeutic approaches that generally suppress the immune system, tolerance induction would provide a sustained resolution of the disease without compromising the immune system's capacity to fight infections and malignancies.
In this study, bone marrow cells from male mice were transplanted into female mice of the same strain, followed by monitoring of the number of male cells in their blood. In CGEN-15001 treated animals, successful engraftment of the transplanted bone marrow cells was observed, while in control animals the transplanted cells were rejected. These results suggest that treatment with CGEN-15001 induces immune tolerance towards the transplanted cells. Additional data will also be presented for CGEN-15001 supporting this highly desired mechanism of action in type 1 diabetes and multiple sclerosis animal models.
CGEN-15001 was injected into the skin graft starting on the day of disease induction, and the skin was subsequently analyzed for psoriatic histological characteristics. Results of this study demonstrated that treatment with CGEN-15001 was highly efficient in the prevention of psoriasis. Currently there is no cure for psoriasis, and treatment may include topical steroids, phototherapy, and systemic agents that suppress the immune system.
7:06AM Compugen drug candidate demonstrates high effectiveness in Type I Diabetes animal model (CGEN) 9.42 : Co announces that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.
Results of the study demonstrate that treatment with CGEN-15001 prevented development of diabetes throughout the 4 months of follow-up. Animals treated with CGEN-15001 maintained normal blood glucose levels compared with untreated animals that developed high blood glucose. The sustained duration of response following a short-term treatment with CGEN-15001, also observed previously in other disease models of autoimmunity, suggests that CGEN-15001 turns off the autoimmune process and may potentially lead to restoration of immune tolerance and resolution of autoimmunity, thereby arresting disease progression.
No doubt: Up!!!
The bigger question is, where does it go from here? The PPS that is.....
Compugen was worth the wait
Gali Weinreb
Compugen shows life sciences companies that invest heavily in science can achieve a breakthrough, even after the capital market has given up on them.
5 August 13 16:43, Gali Weinreb
Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN), founded in the 1990s, was one of the prominent companies in the bio-informatics wave (combining computers and biology) that swept the world. It was believed at the time that cracking the genome and other advances in biology would move the drug discovery process from the laboratory to the computer. But the revolution stalled. Although computer systems improve the drug discovery process, most of the work is still done in the laboratory. Meanwhile, bio-informatics companies were stuck.
Compugen developed a system for automated data mining of biological information from a range of sources. When it was floated on Nasdaq in 2000, its business model was based on the sale of its data mining services to big pharma companies as user fees. Although it signed many cooperation agreements, revenue never exceeded a few million dollars a year.
In 2004, Compugen changed its business model to independently discover and develop drugs on the basis of its computing capabilities. It replaced all its management, board of directors, and a substantial part of its employees (mathematicians replaced biologists). But this did not help either, until the company found the right business model.
In 2010, Compugen decided to focus only on immune checkpoint drugs - molecules that induce the immune system to attack malignant tumors itself. One drug from this group, Yervoy, developed by Bristol Myers Squibb Co. (NYSE: BMY), was a great success, and other pharmaceutical companies rushed after other molecules from this group. Compugen's agreement today with Bayer Healthcare suggests that the bet paid off.
Compugen's story teaches that life sciences companies that invest heavily in time and effort in science over many years can achieve a breakthrough, even after the capital market has given up on them. This assumes that the outstanding science is accompanied by successful management (CEO Dr. Anat Cohen-Dayag) and a party that backs the company financially or can keep capital market enthusiasm alive (chairman Martin Gerstel).
But the lesson of the story is that it is not necessarily worthwhile to accompany a life sciences company all the way. Although Compugen's current market cap is double its IPO value, there were times when it was traded at a 90% discount on its IPO price.
Early investors in companies with such long roads rarely make a profit. When was it worthwhile to invest in Compugen? In 2010, when Cohen-Dayag announced that it was again changing direction, but by then, the market found it difficult to believe.
Published by Globes [online], Israel business news - www.globes-online.com - on August 5, 2013
Could be just the "tip of the iceberg"...
Al
6:26AM Compugen announces collaboration and license agreement with Bayer (BAYRY) for antibody-based cancer immunotherapies (CGEN) 5.46 : Co announced the signing of a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators. Under the terms of the agreement, Bayer HealthCare (BAYRY) and Compugen will jointly pursue a preclinical research program. Subsequently, Bayer will have full control over further development and have worldwide commercialization rights for potential cancer therapeutics. Under the agreement Compugen will receive an upfront payment of $10 million, and is eligible to receive over $500 million in potential milestone payments for both programs, not including milestone payments of up to $30 million associated with preclinical activities. Additionally, Compugen is also eligible to receive mid to high single digit royalties on global net sales of any resulting products under the collaboration.
Compugen Announces Collaboration and License Agreement with Bayer for Antibody-Based Cancer Immunotherapies
Compugen Ltd. - Ordinary Shares (MM) (NASDAQ:CGEN)
Intraday Stock Chart
Today : Monday 5 August 2013
Click Here for more Compugen Ltd. - Ordinary Shares (MM) Charts.
Compugen Ltd. (NASDAQ: CGEN) announced today the signing of a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators. Under the terms of the agreement, Bayer HealthCare (Bayer) and Compugen will jointly pursue a preclinical research program. Subsequently, Bayer will have full control over further development and have worldwide commercialization rights for potential cancer therapeutics.
Under the agreement Compugen will receive an upfront payment of USD 10 million, and is eligible to receive over USD 500 million in potential milestone payments for both programs, not including milestone payments of up to USD 30 million associated with preclinical activities. Additionally, Compugen is also eligible to receive mid to high single digit royalties on global net sales of any resulting products under the collaboration.
“Bayer is committed to translating the science of cancer research into effective therapies helping people affected by cancer live longer and improve their quality of life,” said Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery. “Antibody-based immunotherapies are promising approaches in oncology which can stimulate the body’s own immune cells to fight cancer cells. Immunotherapy is one of our focus areas in oncology research. We are looking forward to expanding our portfolio in this area through partnering with Compugen.”
Anat Cohen-Dayag, Ph.D., President and CEO of Compugen, added, “We are very excited to initiate this collaboration with Bayer, a leading global life science company with a broadening oncology franchise, for the development of antibody-based cancer immunotherapies against these two promising novel immune checkpoint targets. In addition, we believe that the prediction and validation of these two targets, through the use of our broadly applicable predictive discovery infrastructure, provides additional validation for our long-term commitment to establishing this unique capability".
The immunotherapy approach aims at combatting cancer by stimulating the body's own immune cells. The tumor and its environment suppress the ability of cancer patients to develop an effective anti-tumor immune response and in this way protect both tumor growth and survival. Compugen has discovered two novel immune checkpoint regulators that potentially play a key role in immunosuppression. Researchers at Compugen are developing specific therapeutic antibodies that are geared to block the immunosuppressive function of these targets and to reactivate the patient's anti-tumor immune response in order to fight cancer.
About Cancer Immunotherapy
Latest cancer immunotherapies have demonstrated impressive clinical benefit, even for end-stage patients with difficult-to-treat tumors such as metastatic melanoma and non-small cell lung cancer. Unlike conventional cancer therapies, which act by directly targeting the cancer cells, resulting often in only transient clinical responses as cancer cells become resistant, clinical responses to cancer immunotherapy tend to be durable, sometimes resulting in dramatic long term survival and absence of resistance or recurrences.
About Compugen
Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of selected product candidates from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen's corporate website at www.cgen.com.
On August 2, 2013 Compugen filed Form-6K with its financial statements for the six months ended June 30, 2013 and will host a public conference call at 10:00 AM ET on Wednesday, August 7, 2013 to discuss these results and any questions with respect to this press release. Further information regarding the conference call is provided in a separate press release issued today and on our website.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, which include statements related to the potential development and commercialization of antibody-based cancer immunotherapies against the Compugen-discovered immune checkpoint targets, potential milestone and royalty payments, and that the collaboration validates Compugen’s predictive discovery infrastructure, include words such as “may,” “expects,” “anticipates,” “potential,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks and other factors are discussed in the "Risk Factors" section of Compugen’s Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.
7:04AM Compugen discloses focused target discovery program for antibody-drug conjugate cancer therapy (CGEN) 5.26 : Co disclosed the initiation of its second focused discovery program, aimed at identification of novel targets for antibody-drug conjugate cancer therapy focusing on clinical situations with poor survival rates and/or recurrent cancers. This second program follows Compugen's successful initial focused discovery program for novel immune checkpoint proteins, a number of which have been incorporated in the Co's Pipeline Program as Fc fusion protein drugs for immunology and/or as therapeutic targets for monoclonal antibody drugs for cancer immunotherapy.
7:56AM Compugen discloses focused target discovery program for antibody-drug conjugate cancer therapy (CGEN) : Co disclosed the initiation of its second focused discovery program, aimed at identification of novel targets for antibody-drug conjugate cancer therapy focusing on clinical situations with poor survival rates and/or recurrent cancers. This second program follows Compugen's successful initial focused discovery program for novel immune checkpoint proteins, a number of which have been incorporated in the Company's Pipeline Program as Fc fusion protein drugs for immunology and/or as therapeutic targets for monoclonal antibody drugs for cancer immunotherapy.
Second program follows initial program that resulted in discovery of multiple novel immune checkpoint molecules and establishment of Pipeline Program.
Initial discoveries from new program anticipated before year-end
Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy
Today : Tuesday 2 April 2013
Compugen Ltd. (NASDAQ: CGEN) disclosed today the initiation of its second focused discovery program, aimed at identification of novel targets for antibody-drug conjugate (ADC) cancer therapy focusing on clinical situations with poor survival rates and/or recurrent cancers. This second program follows Compugen's successful initial focused discovery program for novel immune checkpoint proteins, a number of which have been incorporated in the Company's Pipeline Program as Fc fusion protein drugs for immunology and/or as therapeutic targets for monoclonal antibody (mAb) drugs for cancer immunotherapy.
Cancer therapy through ADCs, whereby the antibody delivers a cytotoxic drug directly and specifically to the cancer cell in order to induce direct killing of the cells, addresses an area of high unmet medical need and is of great interest to the pharma industry. However, the lack of suitable ADC targets is a major problem. This provides an opportunity for Compugen to serve as a key source of such potential targets and their mAbs.
Dr. Anat Cohen-Dayag, president and CEO of Compugen, stated, “Concurrent with our further research and development activities and collaboration discussions involving our leading Pipeline Program product candidates, we are pleased to disclose this second focused discovery effort, which was a previously stated objective for 2013. Based on the success of our first such effort, we expect initial ADC target discoveries to be added to our pipeline by yearend, thus further expanding the scope and diversity of the cancer therapy arm of our pipeline.”
The new discovery platform is designed to provide hypothesis-driven analysis of complex sets of expression and clinical data to predict proteins that can serve as novel mAb targets. The platform is based on the integration of multiple proprietary systems, tools, and algorithms from Compugen’s existing predictive discovery infrastructure with additional new specialized algorithms and queries geared towards ADC target discovery. Through the use of this discovery platform, utilizing data from numerous clinically annotated biological samples from various solid cancers, Compugen intends to identify potential high value targets expressed on the surface of various types of cancer cells that are associated with poor clinical outcomes, such as low overall survival and short relapse-free survival. A planned additional use of the discovery platform is the identification of mAb targets associated with tumors unresponsive to certain treatments, thereby potentially providing a more personalized therapeutic approach based on the target's expression level in individual patients.
About ADC Cancer Therapy and Cancer Immunotherapy
ADC cancer therapy destroys cancer cells through the use of an antibody or antibody fragment linked to a high-potency cytotoxic agent, called the payload. Unlike traditional cancer therapeutics, ADC therapy is designed to target and destroy only the cancer cells. The antibody specifically targets the cancer cell, where the payload is released and selectively kills the cancer cell. ADCs against a number of targets, both in solid and hematologic tumors, have already demonstrated clinical success, with two ADC products gaining FDA approval in the past two years.
Cancer immunotherapy, such as that based on immune checkpoint blockade, is designed to stimulate the patient’s own immune system to mount durable anti-tumor immunity and tumor destruction, and does not rely on toxic agents to destroy the cancer. Clinical studies employing mAb blockade of immune checkpoints have shown unprecedented durable therapeutic responses that offer a possible cure of metastatic disease. Antibodies targeting immune checkpoints have been termed “the next frontier" in the treatment of cancer, with the first such product receiving FDA approval in 2011.
ADC cancer therapy and cancer immunotherapy are both considered major breakthroughs in treating cancer, and for both, the identification of appropriate targets is critical and has proven very difficult using traditional discovery approaches.
CGEN $4 "Compugen announces $15 mln funding agreement for its Keddem subsidiary (CGEN) 3.94 : Co announced the signing of an agreement with a private U.S.-based investment company pursuant to which up to $15 mln in milestone related equity financing will be made available to Keddem Bioscience, currently a wholly owned subsidiary of Compugen. This financing will be used to further develop and commercialize a unique technology platform that has been designed to consistently enable the discovery of small molecule modulators for potentially any given protein target. Under the agreement, the new investor will obtain a majority equity interest in Keddem, with Compugen maintaining a minority interest and certain future preferential access rights to utilize the Keddem technology with Compugen discovered drug targets." BRIEFING
8:21AM Compugen announces discovery of two novel immune checkpoint targets for cancer immunotherapy (CGEN) 3.72 : Co announced the discovery and initial validation of two new drug target candidates for monoclonal antibody (mAb) cancer therapy. These new candidates have been shown to be expressed in multiple types of tumors and were shown to have an immunomodulatory activity in affecting both innate and adaptive immune responses, thus providing the potential for an efficient and targeted approach in cancer treatment.
By offering a different mode of action from Compugen's other immune checkpoint candidates, these molecules further broaden the scope of the Company's Pipeline Program for monoclonal antibody treatment of cancer. In recent in vitro studies, both of these immune checkpoint molecules have shown distinct activity inhibiting two key subtypes of immune cells, Natural Killer (NK) cells and T cells. These key immune cell subtypes act to recognize and kill tumor cells and have critical roles in the response of the immune system to tumor development.
10:25AM Compugen postpones issuance of third quarter 2012 report and associated conference call to November 5 due to expected severe weather conditions (CGEN) 3.72 : The issuance of the report and the call were previously planned for Tuesday, October 30, 2012 at 10 a.m. ET.
Compugen's CEO Discusses Q2 2012 Results - Earnings Call Transcript
http://seekingalpha.com/article/787691-compugen-s-ceo-discusses-q2-2012-results-earnings-call-transcript?source=yahoo
Compugen and Merck Serono Ventures to Jointly Establish New Biomarker Company Neviah Genomics Ltd.
Today : Monday 25 June 2012
Merck Serono, a division of Merck, Darmstadt, Germany, and Compugen Ltd. (NASDAQ: CGEN) today announced the establishment of Neviah Genomics, a novel start-up company focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity. Neviah Genomics will be operating out of the Merck Serono Israel Bioincubator. Merck Serono Ventures will provide the initial funding for Neviah Genomics. Compugen will utilize certain proprietary predictive discovery technologies and receive an equity ownership in the new company and a right to royalties from potential future sales. Further financial details of the agreement were not disclosed.
Neviah Genomics represents the first investment within the framework of the recently formed Merck Serono Israel Bioincubator program. As such, Neviah Genomics will operate out of the state-of-the-art facilities inaugurated last month at Merck Serono’s Israeli R&D center Inter-Lab, which offers 600 square meters of infrastructure and a wide range of incubation services for the program's new start-ups.
This agreement follows a successful collaboration between Merck Serono and Compugen for the discovery of "biomarker signatures" for drug induced toxicity during 2009. Merck Serono and Compugen believe that establishment of Neviah Genomics with the combined capabilities of the two companies could satisfy the growing market need for products to predict toxicity profiles of lead drug candidates at an early stage of development, thereby minimizing attrition and mitigating risk of late-stage drug failure.
Anat Cohen-Dayag, Ph.D., President and CEO of Compugen said, “Following our prior successful collaboration with Merck Serono, we are very pleased to expand this relationship and enter into this new and exciting partnership. We are honored to be the first Israeli company to benefit from the establishment of Merck Serono's Israel Bioincubator and look forward to taking our partnership to the next level.” Dr. Cohen-Dayag continued, “Furthermore, the formation of Neviah Genomics on a 'discovery on demand' basis enables Compugen to both continue its focus on therapeutic monoclonal antibodies and therapeutic proteins in the fields of immunology and oncology, and provide potential future benefits for our shareholders from our equity interest in Neviah and royalties from future product sales.”
“Neviah Genomics is a perfect illustration of our goals behind the establishment of the Israel Biotech Incubator: to leverage Israeli science and know-how and get access to novel products and technologies for the benefit of Merck Serono’s core therapeutic areas,” said Susan Herbert, Executive Vice President, Global Business Development and Strategy at Merck Serono. “In this regard, we are delighted to be collaborating on our first investment with Compugen, one of the premier biotech companies in Israel and a world leading predictive drug discovery company. We believe that our joint technology and resources represent a unique basis for a start-up to enter this emerging field that has the potential to significantly reduce the risk of drug discovery and development.”
Neviah Genomics will benefit from Compugen's sophisticated proprietary computational discovery platforms to develop advanced toxicogenomics diagnostic tests. Developed tests will be used for the prediction of drug-induced toxicity and integrated into a biomarker platform to support the prioritization and development of drug product candidates.
Total Cash (mrq): 24.99M
Total Cash Per Share (mrq): 0.71
Total Debt (mrq): 0.00
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 12.28
Book Value Per Share (mrq): 0.60
Avg Vol (3 month)3: 114,581
Avg Vol (10 day)3: 104,038
Shares Outstanding5: 35.29M
Float: 33.47M
% Held by Insiders1: 10.04%
% Held by Institutions1: 18.20%
Shares Short (as of May 31, 2012)3: 482.40K
Short Ratio (as of May 31, 2012)3: 3.40
Short % of Float (as of May 31, 2012)3: 1.50%
Shares Short (prior month)3: 485.54K
JOKE STOCK. no revenues.
7:19AM On The Wires (WIRES) : Compugen (CGEN) announced the establishment of operations in South San Francisco, California for the development of oncology and immunology monoclonal antibody drug candidates against Compugen-discovered targets. Drug candidates to be developed against Compugen-discovered targets .
That would make perfect sense. I know a lot of money is being pumped into the market though.. Crazy times ahead imo.
Yep its posted:
Zero revenues in the 4th quarter and the net loss for the 4th quarter was $4.4 million.
Might pull back slightly imo.
~ $CGEN ~ Earnings posted, pending or coming soon! In Charts and Links Below!
~ $CGEN ~ Earnings expected on Tuesday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
http://stockcharts.com/h-sc/ui?s=CGEN&p=D&b=3&g=0&id=p88783918276&a=237480049
http://stockcharts.com/h-sc/ui?s=CGEN&p=W&b=3&g=0&id=p54550695994
~ Barchart: http://barchart.com/quotes/stocks/CGEN?
~ OTC Markets: http://www.otcmarkets.com/stock/CGEN/company-info
~ Google Finance: http://www.google.com/finance?q=CGEN
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=CGEN#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=CGEN+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=CGEN
Finviz: http://finviz.com/quote.ashx?t=CGEN
~ BusyStock: http://busystock.com/i.php?s=CGEN&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=CGEN&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=CGEN
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=CGEN
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=CGEN
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=CGEN
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=CGEN
~ MarketWatch: http://www.marketwatch.com/investing/stock/CGEN/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=CGEN
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CGEN
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CGEN&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CGEN&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CGEN&size=l&frequency=60&color=g
http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916
*If the earnings date is in error please ignore error. I do my best.
6:01AM Compugen announces results showing its CGEN-15001T drug may have potential for cancer immunotherapy (CGEN) 5.30 : Co announced results demonstrating the therapeutic potential of CGEN-15001T as a drug target for treatment of multiple cancers by means of monoclonal antibody ("mAb") therapy. These results indicate that CGEN-15001T is expressed on numerous types of cancer, such as carcinomas, sarcomas, melanoma and hematological cancers as well as on immune cells. These findings, together with previous results supporting its active immunomodulatory effect, 'strongly support CGEN-15001T's potential as a powerful drug target for treatment of various solid and hematological cancers, an area of great interest to the pharmaceutical industry.'
Compugen to Broaden and Accelerate Monoclonal Antibody Program for Oncology and Immunology
$8 million towards expanded program will be provided by Baize Investments via second research funding agreement with Compugen
Business WirePress Release: Compugen Ltd. – Tue, Dec 20, 2011 10:30 AM EST
TEL AVIV, Israel--(BUSINESS WIRE)-- Compugen Ltd. (NASDAQ: CGEN - News) announced today that it will significantly broaden and accelerate its monoclonal antibody (mAb) activities for oncology and immunology within its ongoing Pipeline Program. The expanded activities will include a significant increase in the number of mAb candidates being developed in parallel against Compugen-discovered targets in the Pipeline Program, and the planned in-house establishment of certain key mAb preclinical development capabilities that were previously intended to be obtained solely from third parties.
The Company also announced that $8,000,000 towards the expanded program will be provided to the Company under a research funding agreement signed today with Baize Investments (Israel) Ltd. (“Baize“), a private corporation investing in innovative medical technologies. This follows an earlier research funding agreement between the two parties in December 2010, pursuant to which Compugen received $5,000,000 in support of the initiation of the Pipeline Program.
Under the terms of the new agreement, in exchange for its $8,000,000 in funding, Baize will receive a financial interest in certain mAb product candidates that achieve a specified development milestone, or have been licensed out, during the next three years. In addition, Baize has the right, during the first quarter of 2014, to waive its rights to all future benefits from this financial interest in exchange for 1,455,000 Compugen ordinary shares.
Dr. Anat Cohen-Dayag, President and CEO of Compugen, stated, “During the last two years we were pleased to disclose successful validation of a number of our Pipeline Program therapeutic proteins, such as CGEN-15001 and CGEN-15091, in animal models of autoimmune diseases. This progress continues as we concurrently discuss potential arrangements for further product development and commercialization under royalty bearing licenses and other forms of collaboration. With respect to antibody therapeutics for oncology and immunology, the other focus area of our Pipeline Program, our competitive advantage rests on our unique predictive capabilities to discover novel molecular targets for the subsequent development of monoclonal antibodies that serve as the actual drug product candidates. This is in contrast to the discovery of therapeutic proteins, where our predictive capabilities lead directly to the proteins that serve as the basis for product development.”
Dr. Cohen-Dayag continued, “mAbs are the most rapidly growing drug class, with over 20 mAbs already approved for therapeutic use in the U.S. and in addition have demonstrated a higher success rate in development than other drug classes. However, a key continuing challenge is the identification of novel promising targets. To this end, Compugen harnessed its unique predictive capabilities to develop target discovery platforms and now has a growing inventory of promising potential mAb targets in validation. A number of these targets are now approaching the point where further advancement will require the development of mAbs against them.”
Dr. Cohen-Dayag concluded, “Based on our successful in silico prediction and selection of potential mAb target molecules, we are very pleased to be announcing today a significant broadening and acceleration of our mAb therapeutics program, including an increase in the number of targets against which we will concurrently develop mAbs to be advanced to the preclinical stage prior to out-licensing. Furthermore, since our expectation is that we will have an ongoing need to create and develop mAbs as we continue discovering new targets, we believe it is in our best interest to establish an in-house capability for further mAb development activities. This in-house capability would be in addition to reliance on third parties under arrangements that would normally include sharing of future profits from the resulting mAb product candidates.”
Murray Goldman, Baize’s Chairman, stated, “We are pleased with the progress achieved by Compugen with respect to its Pipeline Program in general and the specific product candidates in which we have a financial interest, and we are proud to have been of assistance in the Program’s initiation in late 2010. Therefore, we are now very much looking forward to expanding this relationship by focusing on accelerating the development in parallel within the Pipeline Program of mAbs against a number of promising Compugen discovered targets in oncology. This is anticipated to lead to significant new therapeutic candidates addressing key unmet needs in cancer treatment, which could meaningfully contribute to the well-being of humanity.”
Mr. Martin Gerstel, Chairman of the Board of Compugen, added, “After more than a decade of building the required predictive discovery infrastructure and scientific foundation, during the past few years we have made three critical decisions pertaining to the potential medical and financial opportunities now available to us due to these successful past and ongoing investments. First, we decided to focus our efforts on monoclonal antibodies and therapeutic proteins in the fields of oncology and immunology. Second, our powerful discovery infrastructure enabled us to quickly establish a Pipeline Program of approximately 30 promising early stage candidates. And finally, our continued target discovery success in the mAb arm of our Pipeline Program has now led us to a third decision: to substantially broaden and accelerate this portion of our Pipeline Program to obtain the maximum value from our target discoveries.”
Mr. Gerstel concluded, “A major partner for Compugen in implementing these decisions has been Baize Investments. Our first Research Funding Agreement with Baize, signed in 2010, allowed us to aggressively initiate the Pipeline Program, without exposing our company to increased financial risk in a difficult economic environment, and without significantly diluting the interests of our existing shareholders base that had in large part provided the resources to allow us to create these opportunities. And now, once again, this new agreement with Baize will allow us to significantly broaden and accelerate the advancement of our extremely promising mAb activities within the Pipeline Program, while again protecting the interests of our current shareholders.”
The New Funding Agreement with Baize Investments
In exchange for $8,000,000 in research funding, Baize will receive a financial interest in therapeutic mAb product candidates to be developed against 12 specified Compugen-discovered targets in the field of oncology, provided that any such mAb product candidates either achieves a successful animal disease model during the next three years, and/or is licensed out to third parties for final development and commercialization during such time period. In each such case, Baize’s financial interest in such qualifying mAb product candidate will consist of the right to receive from Compugen a percentage of certain future payments received by Compugen from third parties from any out-licensing for further development and/or commercialization. The percentage for each such qualifying mAb product candidate will be calculated on the date of out-licensing in accordance with a sliding scale, which takes into account the total Baize research funding spent for the development of therapeutic mAbs against the specified 12 Compugen targets to such date, relative to the total amount invested by both Baize and Compugen in such mAbs, provided that Baize will be entitled to no less than ten percent of such future payments related to any qualifying mAb product candidates. In addition, Baize has the right, during the first quarter of 2014, to waive its rights to receive all such future payments in exchange for 1,455,000 Compugen ordinary shares.
About mAb Therapy
Monoclonal antibody (mAb) therapy is a class of biological drugs that bind with high specificity to target cells or proteins. Due to the versatility and specificity of this approach, mAb therapies are being intensively researched and developed as treatments for numerous serious diseases with the expectation of higher efficacy and fewer side effects compared to traditional chemical drugs. For cancer therapy, a mAb may inhibit cellular processes critical for tumor growth, stimulate the patient's immune system to attack the target cancerous cells, or be used for targeted delivery of chemotherapy specifically to the cells identified by the antibodies. DataMonitor estimated the global monoclonal antibodies market to reach $65 billion by 2016. Moreover, according to an analysis done by Tufts University the rate of success for mAb therapeutics from first use in humans to regulatory approval is more than double that of traditional chemical drugs.
7:03AM Compugen CGEN-15001 pre-clinical data presented at International Conference on immune tolerance (CGEN) 4.19 : Co announced that CGEN-15001 was the subject of a presentation by Joseph Podojil, Ph.D. of the Feinberg School of Medicine Northwestern University, at the 2nd International Conference on Immune Tolerance, now being held in Amsterdam. This is the first time that scientific information related to CGEN-15001's therapeutic potential is being presented to the scientific community. In his talk, Dr. Podojil presented data demonstrating that administration of CGEN-15001 in the experimental autoimmune encephalitis (EAE) animal model of multiple sclerosis (MS) resulted in a dramatic improvement of disease symptoms and abolishment of spontaneous relapses. In addition, the study results demonstrated that short-term treatment with CGEN-15001 lead to long-term inhibition of disease symptoms as well as of the underlying spread of pathological immune responses.
8:07AM Compugen announces the Pulmonary Fibrosis Foundation to fund further therapeutic evaluation studies for Compugen-discovered drug candidate (CGEN) 4.16 : The co and the Pulmonary Fibrosis Foundation announced that the Pulmonary Fibrosis Foundation will provide a grant to scientists to independently evaluate the therapeutic potential of CGEN-25009 for the treatment of idiopathic pulmonary fibrosis. The experiments are designed to further establish the anti-fibrotic properties of CGEN-25009 in multiple animal models of fibrosis, to elucidate the mechanism of CGEN-25009's anti-fibrotic effects, and to prioritize potential biomarkers for the study of CGEN-25009 in patients with idiopathic pulmonary fibrosis... Co says that "although our primary business development efforts are directed towards our oncology and immunology Pipeline Program and 'discovery on demand' activities, we are now in various discussions for arrangements with other organizations to advance certain of these earlier discoveries, including a number of promising novel peptides, largely without the need for further Compugen financial resources, such as the collaboration being announced today."
Compugen Announces Validation of Two Immune System Modulating Drug Candidates
Novel immunomodulatory proteins demonstrate significant therapeutic potential for autoimmune diseases
New drug candidates based on two B7/CD28-like proteins discovered through use of Compugen’s Protein Family Members Discovery Platform
Press Release Source: Compugen Ltd. On Tuesday September 13, 2011, 7:00 am EDT
TEL AVIV, Israel & NEW YORK--(BUSINESS WIRE)-- Speaking today at the Rodman & Renshaw Annual Global Investment Conference in New York City, Martin Gerstel, chairman of Compugen Ltd. (NASDAQ:CGEN - News), reviewed the current status of the Company and announced the validation of two therapeutic product candidates, CGEN-15021 and CGEN-15091, in various autoimmune disease animal models. These two molecules are soluble proteins based on two B7/CD28-like proteins recently discovered by Compugen. In view of its key role in modulating immune response, the B7/CD28 family of proteins is of high interest in medical research and to the pharmaceutical industry, and these newly discovered molecules share key characteristics with this protein family. In addition to the potential use of CGEN-15021 and CGEN-15091 as protein therapeutics for multiple autoimmune diseases, the two proteins they are based on are predicted to have utility as drug targets for monoclonal antibody therapy in oncology.
CGEN-15021 and CGEN-15091 are both soluble fusion proteins, each combining the extracellular domain of one of the newly discovered B7/CD28-like proteins and an Fc antibody fragment. Fusion to an Fc antibody fragment is an established methodology to create soluble long-acting therapeutic proteins. The results being announced today relate to the recent validation of CGEN-15021 in animal disease models of both multiple sclerosis and rheumatoid arthritis, and of CGEN-15091 in an animal disease model of multiple sclerosis. In each of these disease models, the Compugen fusion proteins demonstrated dramatic therapeutic effects in ameliorating disease symptoms. In addition, in earlier in vitro experiments, CGEN-15021 and CGEN-15091 exhibited inhibition of T cell activation, confirming their predicted role in the modulation of the immune system.
In his presentation (which has been posted on Compugen’s website: www.cgen.com), Mr. Gerstel stated, “The discovery process for these two immunomodulatory proteins is an excellent example of the power and uniqueness of the broad based scientific infrastructure for predictive discovery that has been established at Compugen over the past decade. This infrastructure now allows the rapid development of accurate in silico capabilities for the prediction of innovative therapeutic solutions in selected areas of unmet medical need. In this case, we initially directed these capabilities to the B7/CD28 protein family, a protein family of very high industry interest due to its key role in regulating immune responses, and one with significant therapeutic potential in major pathological conditions, such as autoimmune diseases, transplantation and cancer.”
Mr. Gerstel continued, “Within approximately six months, we had integrated multiple components of our infrastructure capabilities to develop the Protein Family Members Discovery Platform, which during its initial discovery process, predicted nine new proteins sharing characteristics with the B7/CD28 protein family. The first three of these nine, consisting of the previously disclosed CGEN-15001 which is currently moving forward in our Pipeline Program, and the two proteins for which positive in vivo results are being announced today, have now been validated in established animal disease models. In addition, we subsequently extended this discovery capability beyond the B7/CD28 family, as well as developing additional capabilities for the discovery of other types of immune related proteins, some of which are now beginning the validation process.”
Mr. Gerstel continued, “With respect to today’s disclosure, the in vitro validation experiments and the in vivo study in a multiple sclerosis animal model of CGEN-15021 and CGEN-15091 were part of Compugen’s long-term research agreement with Prof. Stephen Miller’s laboratory at Northwestern University. The in vivo validation of CGEN-15021 in a rheumatoid arthritis model was conducted at Dr. Richard Williams’ laboratory at the Kennedy Institute of Rheumatology, Oxford University. Having long-term relationships with leading scientists at academic laboratories with well established assays and animal models, enables Compugen to quickly and efficiently validate its new discoveries.”
Mr. Gerstel concluded, “We enthusiastically look forward to the further development of these very attractive drug candidates, and to the ongoing application of our unique capabilities to additional areas of unmet medical need.”
About the B7/CD28 Protein Family of positive and negative co-stimulatory proteins
Members of the B7/CD28 families have been intensively studied over the past decade and have brought much excitement to the field of immune regulation. The activation and development of an adaptive immune response is initiated by the engagement of a T-cell antigen receptor with an antigenic peptide-MHC complex. The outcome of this engagement is determined by both positive and negative co-stimulatory signals, generated mainly by the interaction between members of the B7 family ligands and their receptors, members of the CD28 family. A growing body of evidence indicates that the dysfunction of immune regulation contributes to the development of autoimmune diseases.
Positive and negative co-stimulatory pathways play critical roles in immune regulation and are considered potential targets for modulating chronic inflammation in autoimmune diseases. To date, one soluble recombinant fusion protein that selectively blocks the co-stimulatory signal mediated by the prototype B7/CD28 pathway has been cleared for marketing in the U.S. for the treatment of moderate to severe rheumatoid arthritis, and is in clinical trials for other autoimmune indications. In addition, a number of clinical and preclinical studies for therapeutic agents targeting these protein families are underway at various companies.
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
235
|
Created
|
08/22/02
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=CGEN
Compugen Ltd., an early stage drug and diagnostic discovery company, offers therapeutic and diagnostic biomarker product candidates for cancer, cardiovascular, and immune-related diseases in North America and Israel. It develops products using computer-based discovery platforms, as well as through analyzing DNA or RNA sequences, gene expression data, protein network data, data related to drugs in development, and drugs already being commercialized. The company?s validated discovery platforms include Splice Variant based Therapeutic Proteins, Nucleic-Acid Disease Markers, Protein Disease Markers, Monoclonal Antibody Targets, Nucleic-Acid Preclinical Toxicity Markers, Non-SNP Drug Response Markers, GPCR Therapeutic Peptide Ligands, New Indications, Disease-Associated Conformation Blockers, and Viral Peptides Discovery. Its therapeutic product candidates include CGEN-241, a splice variant of the MET receptor; CGEN-855, a peptide agonist of the FPRL1 GPCR receptor; CGEN-856 and CGEN-857, the MAS GPCR peptide agonists; CGEN-25007, an antagonist of the gp96 protein; CGEN-25008, a peptide antagonist of the Clusterin protein; CGEN-25009-4, an agonist peptide of the LGR7 receptor; CGEN-54, a splice variant of the MCP-1; CGEN-34, a splice variant of the peptide ANP; and CGEN-50001, a small molecule drug. The company?s diagnostic products include CGEN-144, a variant of the Troponin I biomarker; CGEN-438, a blood based biomarker for lung cancer; CGEN-6, a secreted splice variant protein; and CGEN-327, a biomarker for ovarian cancer. It also develops plant traits to the agbio industry through the use of a platform combining computational genomics, molecular biology, and breeding methods. Compugen has collaboration and license agreements with Roche; Siemens Healthcare Diagnostics, Inc.; Ortho-Clinical Diagnostics; Biosite; Teva Pharmacuetical Industries; Merck & Co.; Medarex, Inc.; and Bayer Schering Pharma AG. The company was founded in 1993 and is based in Tel Aviv, Israel.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |